Kerr C R, Hass I, Drance S M, Walters M B, Schulzer M
Br J Ophthalmol. 1982 Feb;66(2):109-14. doi: 10.1136/bjo.66.2.109.
The cardiovascular effects of topical ophthalmological preparations of 2% epinephrine (EPI), 0.1% dipivalyl epinephrine (DPE), and placebo were studied in double-blind fashion in 20 patients with glaucoma. Both drugs and placebo produced a decrease in heart rate (2 +/- 3 beats/min) which, although small, was highly significant (p less than 0.001). Neither drug not placebo produced a significant effect on mean or systolic blood pressure (BP) over the group as a whole (p greater than 0.1). However, 5 of 20 patients responded to EPI with a significant rise in mean or systolic BP (defined as a change greater than mean change +/- 2 SD), whereas there were no such responses to DPE or placebo. One patient developed marked ventricular ectopy after EPI. We conclude that EPI may cause cardiovascular side effects in a high percentage of patients (25% in this study) through individual susceptibility rather than a predictable effect. DPE, a new epinephrine analogue, appears to be devoid of these effects.
在20例青光眼患者中,以双盲方式研究了2%肾上腺素(EPI)、0.1%双特戊酰肾上腺素(DPE)局部眼科制剂及安慰剂的心血管效应。两种药物和安慰剂均使心率降低(2±3次/分钟),尽管降幅较小,但具有高度显著性(p<0.001)。两种药物和安慰剂对整个研究组的平均血压或收缩压均未产生显著影响(p>0.1)。然而,20例患者中有5例对EPI有反应,平均血压或收缩压显著升高(定义为变化大于平均变化±2标准差),而对DPE或安慰剂无此反应。1例患者在使用EPI后出现明显的室性早搏。我们得出结论,EPI可能通过个体易感性而非可预测的效应,在高比例患者(本研究中为25%)中引起心血管副作用。新型肾上腺素类似物DPE似乎没有这些效应。